Table 4 Recent meta-analysis studies on the effect of probiotics in the treatment of H. pylori infection
From: Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections
First author | Year | Sample size | Eradication regimen | Probiotics | Conclusion remarks | Significance | Ref |
|---|---|---|---|---|---|---|---|
Tong et al | 2007 | 1671 | First-line and second-line therapy (triple and bismuth containing quadruple therapy) | B. clausii, Lactobacillus, Saccharomyces | ER: RR: 1.84; 95% CI: 1.34–2.54 AE: 0.44; 95% CI: 0.3–0.6 | Both significant AE was adverse event ER was eradication rate | [169] |
Sachdeva et al | 2009 | 963 | First-line therapy (Triple and Quadruple) | Lactobacillus, Bifidobacterium | ER: 1.91; 95% CI: 1.3–2.6 AE: 0.51; 95% CI: 0.1–2.5 but AE was not significant | Reduction of adverse event rate was not significant | [170] |
Zou et al | 2009 | 1372 | First-line therapy (Triple) | Lactobacillus | ER: 1.78; 95% CI: 1.21–2.62 AE: OR was 0.49 (95% CI = 0.24–1.02) | Both significant | [171] |
Szajewska et al | 2010 | 1307 | First-line therapy (Triple) | S. boulardii | ER: 1.13, 95% CI 1.05–1.21 AE: RR 0.46, 95% CI 0.3–0.7 | Both significant | [172] |
Zheng et al | 2013 | 1163 | First-line therapy (Triple) | Lactobacillus | RR: 1.14; 95% CI: 1.06–1.22 (significant increase of eradication rate) but no significant reduction of overall adverse event | Reduction of adverse event rate was not significant | [173] |
Wang et al | 2013 | 1469 | First-line and second-line therapy (triple and bismuth containing quadruple therapy) | Bifidobacterium, Lactobacillus | ER: 2.066 (95% CI, 1.398–3.055 AE: 0.305; 95% CI, 0.117–0.793) | Both significant | [174] |
Zhu et al | 2014 | 2259 | standard triple H. pylori | Lactobacillus, Bifidobacterium, Saccharomyces | ER: 1.67 (95%CI: 1.38–2.02) AE: (OR = 0.49, 95%CI: 0.26–0.94 | Both significant | [175] |
Dang et al | 2014 | 4459 | First-line therapy (Triple) | L. acidophilus, L. casei DN-114001, L. gasseri, Bifidobacterium infantis 2036 | Curing rate was significantly increase in probiotics (RR: 1.11; 95%CI: 1–1.1) as well as reduce of adverse event (RR: 0.73; 95%CI: 0.5–0.9) | Both significant | [176] |
Zhang et al | 2015 | 6997 | First-line and second-line therapy (triple And bismuth containing quadruple therapy) | Lactobacillus, Bifidobacterium, Streptococcus, Saccharomyces, Enterococcus, Bacillus | ER: RR = 1.13; 95%CI: 1.10–1.16 AE: RR = 0.59; 95%CI: 0.48–0.71 | Both significant | [177] |
Lu et al | 2016 | 3349 | First-line therapy (triple) | Lactobacilli, Bifidobacteria, Bacillus clausii, E. faecium | ER: OR 1.44, 95% CI: 0.87, 2.39 but not significant AE: probiotics did improve the adverse effects OR 0.56, 95% CI: 0.31, 1.01 | Both not significant | [178] |
Lu et al | 2016 | 2306 | First-line therapy (Triple) | Lactobacillus, Bifidobacterium | Eradication rate in probiotic supplementation group was significantly higher than control (RR: 1.15; 95%CI: 1.1–1.2) and reducing adverse event (RR: 0.71; 0.5–0.9) probiotic supplementation increased eradication of triple therapy in both 7 and 14-days | Both significant | [179] |
Si et al | 2017 | 2466 | First-line therapy (bismuth containing quadruple therapy) | Lactobacillus | Eradication rate was significant increase in probiotics (89% vs. 84.7% for first-line) (91% vs. 73.8% for second-line) | significant | [180] |
Losurdo et al | 2018 | NA | NA | Lactobacillus | ER: UBT value: 8.61% vs. 0.19% AE: 1, 95%CI: 0.06–18.08 not siginificANT FOR AE | Reduction of adverse event rate was not significant | [181] |
Shi et al | 2019 | 8924 | First-line therapy (Triple and Quadruple) | Lactobacillus | RR: 1.14; 95%CI: 1.10–1.18 (significant increase of eradication rate) and reduced side effects | Both significant | [182] |
Yu et al | 2019 | 724 | First-line therapy (Triple | Lactobacillus | Eradication rate was significantly increase in Lactobacillus supplement group (RR: 1.1; 95%CI: 1–1.2) and derease significantly adverse event (RR: 0.36; 95%CI: 0.1–0.7) | Both significant | [183] |
Pourmasoumi et al | 2019 | 525 | First-line therapy (Triple and Quadruple) | Lactobacillus, Bifidobacterium Saccharomyces | Eradication: RR: 1.28; 95% CI: 1.15–1.43 Adverse: RR: 0.90; 95% CI: 0.69–1.16 | Both significant | [184] |
Zhou et al | 2019 | 3592 | First-line therapy (Triple) | S. boulardii | ER: 1.09, 95% CI:1.05‐1.13 AE: RR = 0.33, 95%CI:0.16‐0.69 | Both significant | [185] |